Joseph Nesheiwat, MD
Rheumatology · Baton Rouge, LANPI 1417061912
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 829 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 32.8% of the total.
Across 829 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Amgen$5K
- UCB, Inc.$2K
- Novartis$1K
- Johnson & Johnson$652
- Lilly USA, LLC$633
- plus $2K from 18 others
What the payments were for
- Food & beverage$17,32898%
- Education$2672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 247 | $5,774 |
| Amgen(2 entities) | 228 | $4,706 |
| UCB, Inc. | 138 | $2,331 |
| Novartis | 69 | $1,261 |
| Johnson & Johnson | 19 | $652 |
| Lilly USA, LLC | 30 | $633 |
| Pfizer | 27 | $548 |
| E.r. Squibb & Sons, L.L.C. | 17 | $377 |
| Mallinckrodt Hospital Products Inc. | 8 | $283 |
| Regeneron Healthcare Solutions, Inc. | 7 | $161 |
| Aurinia Pharma U.S., Inc. | 6 | $127 |
| Fresenius Kabi USA, LLC | 5 | $127 |
| Bristol Myers Squibb | 9 | $119 |
| ANI Pharmaceuticals, Inc. | 5 | $113 |
| Janssen Scientific Affairs, LLC | 1 | $103 |
| Hikma Pharmaceuticals USA | 4 | $89 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $40 |
| Organon | 1 | $34 |
| Sanofi | 1 | $24 |
| AstraZeneca | 1 | $23 |
| CSL Behring | 1 | $21 |
| Bioventus LLC | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,596 in reported general payments places this provider in the 75th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 130 | $978,196 |
| RinvoqUpadacitinib | 71 | $467,063 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $445,734 |
| Humira(Cf) PenAdalimumab | 55 | $432,616 |
| TremfyaGuselkumab | 19 | $258,779 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $255,810 |
| KevzaraSarilumab | 52 | $229,406 |
| TymlosAbaloparatide | 82 | $215,826 |
| Humira(Cf)Adalimumab | 23 | $177,772 |
| Teriparatide | 67 | $143,281 |
| EnbrelEtanercept | 18 | $136,599 |
| Cimzia (2 Pack)Certolizumab Pegol | 19 | $116,971 |
| Taltz AutoinjectorIxekizumab | 14 | $101,986 |
| Actemra ActpenTocilizumab | 19 | $82,589 |
| OtezlaApremilast | 17 | $80,778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Savella | $5,774 | $656,231113 claims |
| CSL BehringPrivigen | $21 | $445,73416 claims |
| Johnson & JohnsonTremfya | $652 | $258,77919 claims |
| SanofiKevzara | $24 | $229,40652 claims |
| AmgenEnbrel, Otezla | $4,706 | $217,37835 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,331 | $116,97119 claims |
| Lilly USA, LLCForteo | $633 | $51,47111 claims |
| Hikma Pharmaceuticals USABuprenorphine | $89 | $2,43017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Baton Rouge
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
- Randall BeylBaton Rouge$112K
- Chad HilleBaton Rouge$52K
- Ronald CerutiBaton Rouge$29K
- Jen ErbilBaton Rouge$17K
- Hector MenaBaton Rouge$15K
- Stephen PolletBaton Rouge$14K
- Khanh HoBaton Rouge$12K
- Angele BourgBaton Rouge$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.